Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 13/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.51 |
| ▸ | CDK2 | P24941 | 5/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | CCNH | P51946 | 1/20 | 0.44 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.44 |
| ▸ | MAST3 | O60307 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2260487 | 1.00 | MAPK1 (0.51) | MAPK1CCNE1CDK2TAS1R3TAS1R1 | |
| SCHEMBL10166410 | 1.00 | MAPK1 (0.51) | MAPK1CCNE1CDK2TAS1R3TAS1R1 | |
| SCHEMBL558579 | 1.00 | MAPK1 (0.51) | MAPK1CCNE1CDK2TAS1R3TAS1R1 | |
| SCHEMBL2260067 | 1.00 | MAPK1 (0.51) | MAPK1CCNE1CDK2TAS1R3TAS1R1 | |
| SCHEMBL2255931 | 0.93 | MAPK1 (0.52) | MAPK1CCNE1CDK2MAPK8 | |
| SCHEMBL558800 | 0.93 | MAPK1 (0.52) | MAPK1CCNE1CDK2MAPK8 | |
| SCHEMBL559266 | 0.93 | MAPK1 (0.52) | MAPK1CCNE1CDK2CDK7CCNH | |
| SCHEMBL559764 | 0.93 | MAPK1 (0.52) | MAPK1CCNE1CDK2CDK7CCNH | |
| SCHEMBL558887 | 0.92 | MAPK1 (0.51) | MAPK1CCNE1CDK2CDK7CCNH | |
| SCHEMBL2333969 | 0.89 | MAPK1 (0.51) | MAPK1CCNE1CDK2MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | MAPK1 1/4885CCNE1 523/4885CDK2 125/4885 |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | MAPK1 1/4885CCNE1 523/4885CDK2 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.